A Phase 2 interventional study of Placebo Comparator: Placebo and Active Comparator: TU2670 320mg in Endometriosis, sponsored by TiumBio Co., Ltd.. Completed at 40 sites in 5 countries. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-08-13.
Sponsored by TiumBio Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Endometriosis with a site in Poland — 3 open to participants now, 4 under way, none of them phase 3. Endometriosis · Poland.
Among the 29 studies in Endometriosis with a site in Poland, this one is the 20th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2021, is one of 14 in phase 2, and was the 21st registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →3 of the 29 studies in Endometriosis with a site in Poland are open now. Recruiting first, the newest first:
Poznan University of Physical Education · Sites in Poland
Ages 18–90 · Healthy volunteers
Jagiellonian University · Sites in Poland
Ages 18–45 · Women only
Jagiellonian University · Sites in Poland
Ages 18–40 · Women only
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 67 across 542 interventional studies indexed under Endometriosis.
Median enrollment 187 across the 27 interventional studies, 330 across the 2 observational. Of the 22 that completed or were terminated, 11 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 29 have an industry lead sponsor. The 10 most frequent:
TiumBio Co., Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
TiumBio Co., Ltd. has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Endometriosis with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07260669Gesynta Pharma ABA Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Endometriosis with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Protocol for TU2670 is to investigate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of TU2670 in subjects with moderate to severe endometriosis-associated pain.
Treatment Groups and Duration:
Following a washout period of up to 12 weeks, subjects will enter a screening period of up to 12 weeks including an observation period consisting of a complete menstrual cycle.
Subjects will be randomly assigned in a 1:1:1:1 ratio to receive either 12 weeks of TU2670 320 mg QD, TU2670 240 mg QD, TU2670 120 mg QD, or matching placebo. TU2670 or a matching placebo will be administered in the clinic on Day 1. Subjects in the PK subset population will also receive the following additional doses in the clinic: Day 2 (after collection of the 24-hour PK sample); the dose on the day scheduled for subsequent serial PK sample collection (Week 4 or Week 5); and the next scheduled dose (after collection of the 24-hour PK sample). All other doses can be taken by the subject at home. Following the end of treatment, subjects will be followed up for safety for 12 weeks.
Statistical Methods:
All formal statistical tests will be done at the 5% 2-sided significance level. Point estimates will have 2 sided 95% confidence intervals (CIs) where applicable.
Where appropriate, variables will be summarized descriptively (frequency and percent will be summarized for categorical variables; n (number of available subjects), mean, standard deviation [SD], median, minimum, and maximum will be presented for continuous variables) by study visit and by treatment group.
Statistical summaries will be presented for the changes from baseline to each time point in efficacy endpoints that it is applicable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 Placebo capsules
Drug: Placebo Comparator: Placebo
320mg, QD
Drug: Active Comparator: TU2670 320mg
240 mg, QD
Drug: Active Comparator: TU2670 240mg
120 mg, QD
Drug: Active Comparator: TU2670 120mg
4 x placebo capsules, QD
320mg (80mg x 4), QD
240mg (80mg x 3 + placebo x 1), QD
120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
overall pelvic pain
Change from baseline to 12 weeks of treatment of the mean dysmenorrhea score (defined as mean overall pelvic pain score on menstrual bleeding days) as measured by the Numeric Rating Scale(minimum 0, maximum 10, higher score mean a worse outcome) over the past month.
Time frame: 12 weeks
mean Numeric Rating Scale pain score
Change from baseline to 12 weeks of treatment of the mean Numeric Rating Scale pain score(minimum 0, maximum 10, higher score mean a worse outcome) for non-menstrual pelvic pain (mean Numeric Rating Scale pain score on non menstrual bleeding days)
Time frame: 12 weeks
mean overall pelvic pain Numeric Rating Scale pain score
Change from baseline to 12 weeks of treatment of the mean overall pelvic pain Numeric Rating Scale pain score (mean Numeric Rating Scale pain score(minimum 0, maximum 10, higher score mean a worse outcome) over all 28 days)
Time frame: 12 weeks
mean Numeric Rating Scale dyspareunia score
Change from baseline to 12 weeks of treatment of the mean Numeric Rating Scale((minimum 0, maximum 10, higher score mean a worse outcome) dyspareunia score
Time frame: 12 weeks
rescue medication
Change from baseline to 12 weeks of treatment of the use of protocol-defined rescue medication (ie, ibuprofen)
Time frame: 12 weeks
Time to increase of dose of rescue medication
Time to increase of dose of rescue medication from 0 week to 12 weeks
Time frame: 12 weeks
Time to decrease of dose of rescue medication
Time to decrease of dose of rescue medication from 0 week to 12 weeks
Time frame: 12 weeks
Modified Biberoglu and Behrman sign and symptom scores
Change from baseline to 12 weeks of treatment of the Modified Biberoglu and Behrman (mB\&B) sign and symptom scores(minimum 0, maximum 3, higher score mean a worse outcome)
Time frame: 12 weeks
Patient Global Impression of Change
Patient Global Impression of Change (minimum 1, maximum 7, higher score mean a worse outcome) at 12 weeks of treatment
Time frame: 12 weeks
Endometriosis Health Profile-5
Change from baseline to 12 weeks of treatment in the Endometriosis Health Profile-5 score(minimum 1(Never), maximum 5(Always), higher score mean a worse outcome)
Time frame: 12 weeks
36-Item Short Form Health Survey
Change from baseline to 12 weeks of treatment of the 36-Item Short Form Health Survey(Scoring meaning is different from the questions but usually lower score mean a worse outcome)
Time frame: 12 weeks
Work Productivity and Activity Impairment Questionnaire: General Health
Change from baseline to 12 weeks of treatment of the Work Productivity and Activity Impairment Questionnaire: General Health (Scoring meaning is different from the questions)
Time frame: 12 weeks
Bone mineral density loss
Change from baseline to 12 weeks of treatment of the bone mineral density as assessed by dual-energy X-ray absorptiometry (DXA)
Time frame: 12 weeks
Ran from Aug 2021 to primary completion in Jan 2024, 29 months.
Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's 29 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TiumBio Co., Ltd.